 Study DFA102E is an extension of Study DFA102, which included a 28-week treatment period with randomized study medication. The purpose of the extension study is to examine the long-term up to 1 year safety, tolerability, and effect on body weight of treatment with pramlintide and metreleptin, administered as separate subcutaneous SC injections, in obese and overweight subjects. 